• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24494 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enstilar (Psoriasis vulgaris)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enspryng (neuromyelitis optica spectrum disorder- NMOSD)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Blincyto ( B-lineage acute lymphoblastic leukemia)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Xeljanz (Juvenile Idiopathic Arthritis - JIA)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vanflyta (Acute Myeloid Leukemia - AML)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vafseo (dialysis-dependent chronic kidney disease - DD-CKD)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Upstaza (AADC deficiency)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Trodelvy (Breast Cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Tecentriq (Hepatocellular Carcinoma - HCC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Piasky (Paroxysmal Nocturnal Hemoglobinuria - PNH)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Minjuvi (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Fustron (Breast Cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Calquence (Chronic Lymphocytic Leukemia - CLL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Brukinsa (Chronic Lymphocytic Leukemia - CLL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Bavencio (Urothelial Carcinoma - UC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Xinclame (ophthalmic antibiotic)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Scemblix (chronic myeloid leukaemia - CML)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Qinlock (GIST)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Epkinly (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Columvi (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Cen-Capto (Pediatric heart failure)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Tecentriq (NSCLC-first line treatment)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Lynparza(prostate cancer- PC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Lynparza (Breast cancer- BC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Lynparza (advanced ovarian cancer- AOC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (Triple Negative Breast Cancer-TNBC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (metastatic non-squamous non-small cell-NSCLC) lung cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (colorectal cancer - CRC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Beovu (Neovascular (wet) age-related macular degeneration, AMD & polypoidal choroidal vasculopathy, PCV & Diabetic Macular Edema, DME)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Voxzogo (Achondroplasia - ACH)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Tecvayli (Relapsed or refractory multiple myeloma - RRMM)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Zejula (ovarian cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Uptravi (PAH associated with connective tissue disease (PAH-CTD))]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Tecentriq (Subcutaneous injection)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Sotyktu (Plaque psoriasis)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Elrexfio solution for injection (Relapsed or refractory multiple myeloma - RRMM)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Cosentyx (Enthesitis-Related Arthritis - ERA)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-BYFAVO (Procedural sedation and analgesia - PSA)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Amvuttra (Familial Amyloidotic polyneuropathy Stage I~II-FAP)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Adcirca (Pulmonary arterial hypertension - PAH)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding screening for vitamin D-dependent rickets to the Quebec Neonatal Blood Screening Program]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of extracorporeal membrane oxygenation (ECMO) in adults in Quebec: patient characteristics, care trajectories and clinical outcomes, 2017 to 2023]
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. NICE interventional procedures guidance 808
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for severe acute heart failure in adults. NICE interventional procedures guidance 807
2025     National Institute for Health and Care Excellence (NICE) Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal). NICE technology appraisal guidance 1100
2025     National Institute for Health and Care Excellence (NICE) Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy. NICE technology appraisal guidance 1099
2025     National Institute for Health and Care Excellence (NICE) Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over. NICE technology appraisal guidance 1101
2025     National Institute for Health and Care Excellence (NICE) Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor. NICE technology appraisal guidance 1103
2025     National Institute for Health and Care Excellence (NICE) Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1105
2025     National Institute for Health and Care Excellence (NICE) Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal). NICE technology appraisal guidance 1104
2025     National Institute for Health and Care Excellence (NICE) Iptacopan for treating complement 3 glomerulopathy (terminated appraisal). NICE technology appraisal guidance 1102
2025     NIHR Health Technology Assessment programme Microfracture with or without collagen scaffold insertion for adults with chondral or osteochondral defects of the knee: the SISMIC RCT and its challenges during and after the COVID-19 pandemic
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Kinaesthetics (‘science of the perception of body movements’): Do recipients of care and professional carers benefit from its application?]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extracorporeal diagnosis and treatment of liver transplants while avoiding cold preservation]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (Hämophilie A, Hämophilie B) – Addendum zu den Projekten A25-55 und A25-56]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sepiapterin (phenylketonuria) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Givinostat (Duchenne muscular dystrophy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dalbavancin (acute bacterial skin and skin structure infections, from birth < 3 months) – Assessment in accordance with §35a (1c) Social Code Book V ]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [High frequency ablation of the endometrium using a mesh electrode in patients with menorrhagia]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Project A25-54]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Addendum to Project A25-56]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belzutifan (renal cell carcinoma) – Addendum to Project A25-45]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirikizumab (Crohn's disease) - Addendum to Project A25-42]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (transthyretin amyloidosis with cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, ≥ 4 weeks, 3 to < 40 kg) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax and obinutuzumab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (mantle cell lymphoma; monotherapy) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (mantle cell lymphoma; combination with bendamustine and rituximab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Omaveloxolone (Friedreich’s ataxia) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with venetoclax) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for exagamglogene autotemcel (sickle cell disease): Review of the study protocol (Version 1.0) and statistical analysis plan (Version 1.0) – Second addendum to Project A23-49]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, perioperative) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (hepatocellular carcinoma, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rimegepant (prophylaxis of migraine) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rimegepant (migraine, acute treatment) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Datopotamab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Mobile applications for pulmonary rehabilitation - chronic obstructive pulmonary disease]
2025     NIHR Health Technology Assessment programme Acceptance and commitment therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial
2025     Norwegian Medical Products Agency (NOMA) Ketamine for acute suicidal ideation. Protocol for a health technology assessment
2025     NIHR Health Services and Delivery Research programme Design and deployment of digital health interventions to reduce the risk of the digital divide and to inform development of the living with COVID recovery: a systematic scoping review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the program on preventive health check-ups: screening for chronic kidney disease – a rapid review of benefits, harms and target populations
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pentobarbital blood determination by HPLC-MS/MS]
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of Zolbetuximab (Vyloy)
2025     NIHR Health Services and Delivery Research programme Effectiveness and cost-effectiveness of community perinatal mental health services on access, experience, recovery/relapse and obstetric and neonate outcomes: the ESMI-II mixed-methods study
2025     NIHR Health Technology Assessment programme Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices: a systematic review and cost-effectiveness analysis
2025     Scottish Health Technologies Group (SHTG) Optune Gio® tumour-treating field therapy
2025     Scottish Health Technologies Group (SHTG) Intelligent Liver Function Testing (iLFT) for the earlier diagnosis of chronic liver disease (CLD)
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fetal sex determination using circulating cell-free DNA in cases of genetic risk: repatriation of an analysis carried out outside the province of Quebec]
2025     NIHR Health Technology Assessment programme Rapid diagnostic tests to inform clinical decision-making for antifungal stewardship in the ICU: a qualitative study with NHS staff, patients, and their legal representatives
2025     NIHR Health Technology Assessment programme Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
2025     NIHR Health Services and Delivery Research programme Strategies to manage emergency ambulance telephone callers with sustained high needs: the STRETCHED mixed-methods evaluation with linked data
2025     NIHR Health Services and Delivery Research programme Accessibility and acceptability of perinatal mental health services for women from ethnic minority groups: a synopsis of the PAAM study
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Access to breast cancer screening for Québec women aged 40 to 49: issues, considerations and implementation approach]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Overview – Quebec frequent emergency department users 2022-2023]